PL2291374T3 - Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej - Google Patents

Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej

Info

Publication number
PL2291374T3
PL2291374T3 PL09750841T PL09750841T PL2291374T3 PL 2291374 T3 PL2291374 T3 PL 2291374T3 PL 09750841 T PL09750841 T PL 09750841T PL 09750841 T PL09750841 T PL 09750841T PL 2291374 T3 PL2291374 T3 PL 2291374T3
Authority
PL
Poland
Prior art keywords
solifenacin
preparation
pharmaceutically acceptable
acceptable salts
pharmaceutical purity
Prior art date
Application number
PL09750841T
Other languages
English (en)
Inventor
Oliwia Zegrocka-Stendel
Joanna Zagrodzka
Marta Laszcz
Original Assignee
Zakl Farmaceutyczne Polpharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zakl Farmaceutyczne Polpharma S A filed Critical Zakl Farmaceutyczne Polpharma S A
Publication of PL2291374T3 publication Critical patent/PL2291374T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09750841T 2008-05-23 2009-05-22 Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej PL2291374T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL385265A PL385265A1 (pl) 2008-05-23 2008-05-23 Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PCT/PL2009/000054 WO2009142522A1 (en) 2008-05-23 2009-05-22 Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity
EP09750841.0A EP2291374B1 (en) 2008-05-23 2009-05-22 Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity

Publications (1)

Publication Number Publication Date
PL2291374T3 true PL2291374T3 (pl) 2015-12-31

Family

ID=40934126

Family Applications (2)

Application Number Title Priority Date Filing Date
PL385265A PL385265A1 (pl) 2008-05-23 2008-05-23 Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PL09750841T PL2291374T3 (pl) 2008-05-23 2009-05-22 Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL385265A PL385265A1 (pl) 2008-05-23 2008-05-23 Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej

Country Status (7)

Country Link
US (1) US8436182B2 (pl)
EP (1) EP2291374B1 (pl)
JP (1) JP5777513B2 (pl)
KR (1) KR101631268B1 (pl)
ES (1) ES2541668T3 (pl)
PL (2) PL385265A1 (pl)
WO (1) WO2009142522A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
PL385264A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
CN102887894A (zh) * 2011-07-18 2013-01-23 天津市医药集团技术发展有限公司 一种琥珀酸索利那新晶型及其制备方法
CN102875544B (zh) * 2012-09-19 2015-05-20 成都新恒创药业有限公司 琥珀酸索非那新的制备工艺
CN104447734A (zh) * 2014-12-11 2015-03-25 荆楚理工学院 一种琥珀酸索利那新的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001244A (en) 1973-07-23 1977-01-04 G. D. Searle & Co. 1-aryl-3,4-dihydro-2(1h)-isoquinoline carbonyl chlorides
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005007771A1 (en) * 2003-07-23 2005-01-27 Dupont Canada Inc. Coolant liquids having a low dielectric constant and high resistivity for use in fuel cells & other electrochemical reactor stacks
JP2005105795A (ja) * 2003-10-01 2005-04-21 Yoichi Yoshida 曲線仮設足場の親綱支持装置
WO2005087231A1 (ja) * 2004-03-16 2005-09-22 Astellas Pharma Inc. ソリフェナシン含有組成物
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
DE602006020138D1 (de) 2005-06-29 2011-03-31 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
PT1979356E (pt) * 2005-12-21 2013-11-21 Pfizer Prod Inc Carbonilaminopirrolopirazolos, inibidores potentes de cinase
CZ300699B6 (cs) 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
WO2008011462A2 (en) 2006-07-19 2008-01-24 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
EP1943248A2 (en) 2006-08-03 2008-07-16 Teva Pharmaceutical Industries Ltd. Solifenacin base forms and preparation thereof
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny

Also Published As

Publication number Publication date
KR101631268B1 (ko) 2016-06-16
US20110065922A1 (en) 2011-03-17
JP2011521008A (ja) 2011-07-21
EP2291374B1 (en) 2015-04-15
ES2541668T3 (es) 2015-07-23
EP2291374A1 (en) 2011-03-09
JP5777513B2 (ja) 2015-09-09
PL385265A1 (pl) 2009-12-07
US8436182B2 (en) 2013-05-07
WO2009142522A1 (en) 2009-11-26
KR20110016447A (ko) 2011-02-17

Similar Documents

Publication Publication Date Title
IL206500A0 (en) Process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
EP2086945A4 (en) NOVEL PROCESS FOR THE PRODUCTION OF STATINES AND THEIR PHARMACEUTICAL ACCEPTIC SALTS
ZA200906899B (en) Process for preparation of erlotinib and its pharmaceutically acceptable salts
IL238337A (en) A process for preparing pharmaceutical active compounds
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
EP1968943A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF MONTELUCASTAST AND THE PHARMACEUTICALLY SAFE SALTS
IL215065A (en) Proline derivatives, their preparation process, their pharmaceutical compositions and their uses in drug preparation
IL219120A (en) Cyclohaphtha pyridinyl derivatives and their use in drug preparation
PL2400954T3 (pl) Sposób wytwarzania stałych, doustnych postaci solifenacyny i jej farmaceutycznie dopuszczalnych soli
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
PL3067353T3 (pl) Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania
PL2241553T3 (pl) Sposób syntezy iwabradyny i jej soli addycyjnych z kwasem dopuszczalnym farmaceutycznie
SI2736909T1 (sl) Proces za pripravo sitagliptina in njegovih farmacevtsko sprejemljivih soli
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
ZA200902575B (en) Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof
HUP0700756A2 (en) Process for the preparation of pharmaceutical intermediers
HK1169827A1 (en) Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
HUP1000565A2 (en) Process for the preparation of pharmaceutically active compound and intermediers
HK1183488A1 (en) Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
EP2389360A4 (en) METHOD FOR PRODUCING ZOFENOPRIL AND PHARMACEUTICAL ACCEPTIC SALTS THEREFOR
PL2607354T3 (pl) Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem farmaceutycznie dopuszczalnym
ZA201000159B (en) Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof
HU0900777D0 (en) Enviroment-friendly process for the preparation of high purity pharmaceutical composition